Quantitative T1 Mapping for Small Tumor Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional MRI systems face limitations in image resolution, particularly in detecting small tumors less than 2 mm in diameter due to physical and physiological constraints, and conventional contrast agents become less effective at higher magnetic field strengths, leading to inadequate detection of small tumors and cancer cells.
Innovation Solution
The use of quantitative T1 relaxation time mapping with specific molecular imaging agents like SBK2-Tris-(Gd-DOTA)3, which accumulates and retains in tumors for a clinically relevant period, allowing for improved tumor imaging and detection of small tumors by providing a quantitative measure of contrast agent concentration and retention time.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If the magnetic field strength is increased to improve spatial resolution, then image resolution is improved, but contrast is reduced
Solution Approach 1:
The patent develops contrast agents with modified molecular parameters (molecular weight, structure, relaxation properties) that maintain or enhance contrast effectiveness at higher magnetic field strengths (7T), where conventional agents become less effective due to frequency-dependent relaxation mechanisms
Solution Approach 2:
The invention uses composite contrast agent structures combining gadolinium chelates with specific molecular scaffolds (e.g., dendrimers, peptides) to optimize both relaxation efficiency and target specificity, achieving superior contrast at high field strengths while maintaining spatial resolution
2Manufacturing precision
If conventional contrast agents are used at higher magnetic field strengths, then spatial resolution is improved, but contrast agent effectiveness is reduced
Solution Approach 1:
The patent systematically modifies contrast agent parameters including molecular weight (500-5000 Da), relaxation time constants (T1, T2), and magnetic susceptibility to optimize performance at 7T field strength, where conventional agents exhibit reduced relaxivity due to Larmor frequency effects
Solution Approach 2:
The invention introduces molecular targeting ligands (peptides, antibodies) as intermediaries that bind specifically to tumor markers, enhancing local contrast agent concentration and effectiveness at high field strengths where conventional non-targeted agents show reduced contrast
3Ease of operation
If conventional T1-weighted imaging is used, then image acquisition is simple, but the images are non-quantitative and interpretation is subjective
Solution Approach 1:
The patent replaces subjective visual interpretation of T1-weighted images with automated quantitative analysis systems that measure T1 relaxation times and contrast agent concentrations objectively, substituting human perception with precise computational measurement
Solution Approach 2:
The invention implements feedback loops where T1 mapping data is continuously refined through iterative optimization algorithms, comparing measured relaxation curves with theoretical models to achieve precise quantitative measurements of contrast agent concentration and tumor characteristics
4Loss of time
If conventional MRI resolution is used, then scanning time is reduced, but tumors less than 2 mm in diameter cannot be detected
Solution Approach 1:
The patent uses targeted molecular contrast agents that bind specifically to tumor markers before imaging, pre-concentrating the signal at the tumor site. This preliminary targeting enables detection of sub-2mm tumors at conventional resolution without increasing scan time
Solution Approach 2:
The invention optimizes contrast agent relaxation parameters (particularly T1 shortening efficiency) to maximize signal-to-noise ratio at clinical field strengths, enabling enhanced tumor detectability without requiring higher spatial resolution or longer acquisition times
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the detection of tumors as small as 1 mm in diameter and provides a richer data set for tumor characterization, improving image resolution and sensitivity compared to conventional methods, with SBK2-Tris-(Gd-DOTA)3 showing prolonged retention and higher contrast enhancement in tumors.
Implementation Method 1
T1 refers to spin-lattice relaxation
Implementation Method 2
higher frequencies are needed for the radio frequency (RF) to produce NMR because of the Larmor relationship: ω=γB0
Data Source
AI summary
Example apparatus and methods concern determining whether a target material appears in a region experiencing nuclear magnetic resonance (NMR). One method acquires a baseline value for a magnetic resonance parameter (MRP) while the region is not exposed to a molecular imaging agent that affects the MRP and acquires a series of quantitative values for the MRP while the sample is influenced by a molecular imaging agent. Quantitative values may be acquired during a clinically relevant time period (e.g., 60 minutes) during which the change in the MRP (e.g., T1) caused by the molecular imaging agent is at least 90% of the peak change caused by the molecular imaging agent. The molecular imaging agent may be SBK2 and may produce a desired change in T1 for at least thirty minutes in glioblastoma.